For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma

For more information read the patient information leaflet accessible here

  • Home
  • About Tezspire
    What is Tezspire? How does it work? Why were you
    prescribed Tezspire?
  • How to use Tezspire
  • Safety and side effects
  • Resources
  • FAQs

For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire▼ (tezepelumab) for severe uncontrolled asthma

For more information read the patient information leaflet accessible here

  • Home
  • About Tezspire
  • How to use Tezspire
  • Safety and side effects
  • Resources
  • FAQs
  • close
menu

Contact us

Follow the directions in your Homecare pack for a number to contact with your questions.

The information on this website is not a substitute for medical advice. If you have any questions about your condition or the treatment you have been prescribed, please speak to a healthcare professional.

For medical enquiries about AstraZeneca products (including questions on how to take your medicine, to report a side effect or make a complaint), you can also call AstraZeneca's Medical Information team on: 0800 783 0033. Lines are open Monday to Friday, from 9am to 5pm.

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get as advised above.

Discover helpful resources to support you with your treatment

Can't find what you're looking for? Explore frequently asked questions.

Reporting side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.ukhttps://yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get as advised above.

GB-49729 | DOP: February 2024

This is a non-promotional website produced and funded by AstraZeneca.

This site is intended to complement, not replace, the 'Instructions for Use' and 'Patient Information Leaflet' (found in your carton or linked at the top of the page). Refer to these materials for additional important information.

If you have any questions or concerns about your treatment, you should always talk to your healthcare team.

Please see the information in the box above for details on how to report any side effects you may be experiencing.

Tezspire is a registered trademark of the AstraZeneca group of companies

©2024 AstraZeneca All rights reserved. GB-49703 Date of Preparation: March 2024

Legal notice | Privacy policy | Contact us | Cookie policy

Welcome to an AstraZeneca UK produced and funded website

Please select the option that applies to you below.

FOR UK HEALTHCARE PROFESSIONALS

If you are a UK HCP and would like to access information on
Tezspire (tezepelumab), please enter the site using the button below.

This is a promotional website.

FOR UK PATIENTS
OR CARERS

If you are a UK patient, or their carer, prescribed Tezspire (tezepelumab), please enter the site using the button below.

FOR THE GENERAL
PUBLIC

If you are not a UK HCP or
Tezspire (tezepelumab) patient/ carer, this website is not suitable for you.

GB-51556 | DOP: March 2024

Visit astrazeneca.co.uk